<?xml version="1.0" encoding="UTF-8"?>
<collection xmlns="http://www.loc.gov/MARC21/slim">
<record>
  <controlfield tag="001">171665</controlfield>
  <controlfield tag="005">20260527123127.0</controlfield>
  <datafield tag="024" ind1="7" ind2=" ">
    <subfield code="2">doi</subfield>
    <subfield code="a">10.1111/phpp.70084</subfield>
  </datafield>
  <datafield tag="024" ind1="8" ind2=" ">
    <subfield code="2">sideral</subfield>
    <subfield code="a">149421</subfield>
  </datafield>
  <datafield tag="037" ind1=" " ind2=" ">
    <subfield code="a">ART-2026-149421</subfield>
  </datafield>
  <datafield tag="041" ind1=" " ind2=" ">
    <subfield code="a">eng</subfield>
  </datafield>
  <datafield tag="100" ind1=" " ind2=" ">
    <subfield code="a">Álvarez Bobillo, Zita</subfield>
  </datafield>
  <datafield tag="245" ind1=" " ind2=" ">
    <subfield code="a">UV Protection Habits and Preferences in Patients With Distinct Cutaneous Immune‐Mediated Inflammatory Diseases</subfield>
  </datafield>
  <datafield tag="260" ind1=" " ind2=" ">
    <subfield code="c">2026</subfield>
  </datafield>
  <datafield tag="520" ind1="3" ind2=" ">
    <subfield code="a">Background Achieving adequate UV protection can be particularly challenging in patients with cutaneous immune-mediated inflammatory dermatoses (IMIDs), owing to the clinical characteristics and quality-of-life impact of these diseases.
Objectives To compare the UV protection habits and preferences of patients with cutaneous IMIDs, specifically considering expert recommendations for these diseases.
Methods This pilot cross-sectional, observational and analytical cohort study recruited 120 participants (78 female, 42 male; mean age, 40.8 +/- 15.39 years): 20 cases for each IMID (vitiligo, atopic dermatitis, alopecia areata, psoriasis and hidradenitis suppurativa) and 20 healthy controls. Study variables included eye and hair color, BMI, phototype, clinical severity scales for each IMID, the Dermatology Life Quality Index (DLQI) score and a study-specific questionnaire on photoprotection preferences.
Results Daily photoprotection was reported by 40% of participants, with highest adherence (55%) in vitiligo patients. Hat use was generally low (24.17%), except among alopecia areata patients (40%). Overall, 63.3% of participants reported no sunburn in the last year, and 95% used an SPF > 15. Cream was the most commonly used SPF format, followed by spray. Oral photoprotection was known by 33.3% of participants, with highest use reported by vitiligo patients (45%). Compliance with UV protection recommendations for their specific disease was highest among vitiligo patients (70%), but did not exceed 10% for any other IMID.
Conclusions Educating patients with cutaneous IMIDs about appropriate UV protection, tailored to their specific skin disorder, treatments and preferences, is crucial to improve compliance and disease control.</subfield>
  </datafield>
  <datafield tag="506" ind1="0" ind2=" ">
    <subfield code="a">Access copy available to the general public</subfield>
    <subfield code="f">Unrestricted</subfield>
  </datafield>
  <datafield tag="540" ind1=" " ind2=" ">
    <subfield code="9">info:eu-repo/semantics/openAccess</subfield>
    <subfield code="a">by</subfield>
    <subfield code="u">https://creativecommons.org/licenses/by/4.0/deed.es</subfield>
  </datafield>
  <datafield tag="655" ind1=" " ind2="4">
    <subfield code="a">info:eu-repo/semantics/article</subfield>
    <subfield code="v">info:eu-repo/semantics/publishedVersion</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Barandika Urrutia, Iranzu</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Gracia Cazaña, Tamara</subfield>
    <subfield code="u">Universidad de Zaragoza</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Gilaberte Calzada, Yolanda</subfield>
    <subfield code="u">Universidad de Zaragoza</subfield>
    <subfield code="0">(orcid)0000-0001-8034-3617</subfield>
  </datafield>
  <datafield tag="710" ind1="2" ind2=" ">
    <subfield code="1">1007</subfield>
    <subfield code="2">183</subfield>
    <subfield code="a">Universidad de Zaragoza</subfield>
    <subfield code="b">Dpto. Medicina, Psiqu. y Derm.</subfield>
    <subfield code="c">Área Dermatología</subfield>
  </datafield>
  <datafield tag="773" ind1=" " ind2=" ">
    <subfield code="g">42, 2 (2026), [14 pp.]</subfield>
    <subfield code="p">Photodermatol. photoimmunol. photomed.</subfield>
    <subfield code="t">PHOTODERMATOLOGY PHOTOIMMUNOLOGY &amp; PHOTOMEDICINE</subfield>
    <subfield code="x">0905-4383</subfield>
  </datafield>
  <datafield tag="856" ind1="4" ind2=" ">
    <subfield code="s">673414</subfield>
    <subfield code="u">http://zaguan.unizar.es/record/171665/files/texto_completo.pdf</subfield>
    <subfield code="y">Versión publicada</subfield>
  </datafield>
  <datafield tag="856" ind1="4" ind2=" ">
    <subfield code="s">2404531</subfield>
    <subfield code="u">http://zaguan.unizar.es/record/171665/files/texto_completo.jpg?subformat=icon</subfield>
    <subfield code="x">icon</subfield>
    <subfield code="y">Versión publicada</subfield>
  </datafield>
  <datafield tag="909" ind1="C" ind2="O">
    <subfield code="o">oai:zaguan.unizar.es:171665</subfield>
    <subfield code="p">articulos</subfield>
    <subfield code="p">driver</subfield>
  </datafield>
  <datafield tag="951" ind1=" " ind2=" ">
    <subfield code="a">2026-05-27-11:26:06</subfield>
  </datafield>
  <datafield tag="980" ind1=" " ind2=" ">
    <subfield code="a">ARTICLE</subfield>
  </datafield>
</record>
</collection>